N-acetyl-aspartyl-glutamate and inhibition of glutamate carboxypeptidases protects against soman-induced neuropathology

NeuroToxicology

Volumn 48, Issue , 2015, Pages 180-191

  Guo, Huifu ^a   Liu, Jiong ^a   Van Shura, Kerry ^b   Chen, HuaZhen ^a   Flora, Michael N ^a   Myers, Todd M ^b   McDonough, John H ^b   McCabe, Joseph T ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

Author keywords

2 Phosphonomethyl pentanedioic acid (2 PMPA); Brain injury; Effect size; High performance liquid chromatography

Indexed keywords

2 PHOSPHONOMETHYL PENTANEDIOIC ACID; BETA N ACETYLASPARTYLGLUTAMIC ACID; GAMMA GLUTAMYL HYDROLASE; HYDROLASE INHIBITOR; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; NEUROPROTECTIVE AGENT; SOMAN; UNCLASSIFIED DRUG; 2-(PHOSPHONOMETHYL)PENTANEDIOIC ACID; CARBOXYPEPTIDASE; CHEMICAL WARFARE AGENT; DIPEPTIDE; ENZYME INHIBITOR; N-ACETYL-1-ASPARTYLGLUTAMIC ACID; N-ACETYLASPARTYL-BETA-LINKED GLUTAMATE; ORGANOPHOSPHORUS COMPOUND;

AMYGDALOID NUCLEUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CELL COUNT; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG MEGADOSE; ENTORHINAL CORTEX; ENZYME INHIBITION; HISTOCHEMISTRY; LIMBIC CORTEX; LOW DRUG DOSE; MALE; NERVE CELL NECROSIS; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SURVIVAL RATE; TREATMENT RESPONSE; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CELL DEATH; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; NERVE CELL; ORGANOPHOSPHATE POISONING; PATHOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TIME;

ANIMALIA; MAMMALIA; RATTUS;

ANIMALS; BRAIN; CARBOXYPEPTIDASES; CELL DEATH; CHEMICAL WARFARE AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIPEPTIDES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; MALE; NEURONS; NEUROPROTECTIVE AGENTS; ORGANOPHOSPHATE POISONING; ORGANOPHOSPHORUS COMPOUNDS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SOMAN; TIME FACTORS;

EID: 84927940359     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2015.03.010     Document Type: Article

References (74)

1. Apland J.P., Figueiredo T.H., Qashu F., Aroniadou-Anderjaska V., Souza A.P., Braga M.F. Higher susceptibility of the ventral versus the dorsal hippocampus and the posteroventral versus anterodorsal amygdala to soman-induced neuropathology. Neurotoxicology 2010, 31:485-492.
2. Bajgar J. Complex view on poisoning with nerve agents and organophosphates. Acta Med 2005, 48:3-21.
3. Baslow M.H. Evidence that the tri-cellular metabolism of N-acetylaspartate functions as the brain's operating system: how NAA metabolism supports meaningful intercellular frequency-encoded communications. Amino Acids 2010, 39:1139-1145.
4. Baslow M.H., Hrabe J., Guilfoyle D.N. Dynamic relationship between neurostimulation and N-acetylaspartate metabolism in the human visual cortex: evidence that NAA functions as a molecular water pump during visual stimulation. J Mol Neurosci 2007, 32:235-245.
5. Becker I., Lodder J., Gieselmann V., Eckhardt M. Molecular characterization of N-acetylaspartylglutamate synthetase. J Biol Chem 2010, 285:29156-29164.
6. Bergeron R., Coyle J.T., Tsai G., Greene R.W. NAAG reduces NMDA receptor current in CA1 hippocampal pyramidal neurons of acute slices and dissociated neurons. Neuropsychopharmacology 2005, 30:7-16.
7. Borenstein M., Hedges L.V., Higgins J.P.T., Rothstein H.R. Introduction to meta-analysis 2009, John Wiley & Sons, Ltd, Chicester, UK. 1st ed.
8. Bruno V., Wroblewska B., Wroblewski J.T., Fiore L., Nicoletti F. Neuroprotective activity of N-acetylaspartylglutamate in cultured cortical cells. Neuroscience 1998, 85:751-757.
9. Cai Z., Lin S., Rhodes P.G. Neuroprotective effects of N-acetylaspartylglutamate in a neonatal rat model of hypoxia-ischemia. Eur J Pharmacol 2002, 437:139-145.
10. Carpenter K.J., Dickenson A.H. Amino acids are still as exciting as ever. Curr Opin Pharmacol 2001, 1:57-61.
11. Cendes F., Andermann F., Dubeau F., Matthews P.M., Arnold D.L. Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy. Evidence from proton MR spectroscopic imaging. Neurology 1997, 49:1525-1533.
12. Chidlow G., Wood J.P., Sarvestani G., Manavis J., Casson R.J. Evaluation of Fluoro-Jade C as a marker of degenerating neurons in the rat retina and optic nerve. Exp Eye Res 2009, 88:426-437.
13. Cohen J. Statistical power analysis for the behavioral sciences 1988, Psychology Press, Taylor & Francis Group, New York. 2nd ed.
14. Collard F., Stroobant V., Lamosa P., Kapanda C.N., Lambert D.M., Muccioli G.G., et al. Molecular identification of N-acetylaspartylglutamate synthase and β-citrylglutamate synthase. J Biol Chem 2010, 285:29826-29833.
15. Collins T.J. ImageJ for microscopy. Biotechniques 2007, 43:25-30.
16. Collombet J.M., Baubichon D., Four E., Sentenac-Masqueliez C., Lallement G. Effects of soman poisoning on mitochondrial respiratory enzyme activity in the mouse hippocampus and cerebral cortex. Drug Chem Toxicol 2009, 32:405-410.
17. Collombet J.M., Four E., Fauquette W., Burckhart M.F., Masqueliez C., Bernabe D., et al. Soman poisoning induces delayed astrogliotic scar and angiogenesis in damaged mouse brain areas. Neurotoxicology 2007, 28:38-48.
18. Dolgin E. Syrian gas attack reinforces need for better anti-sarin drugs. Nat Med 2013, 19:1194-1195.
19. Engel J., Pedley T.A. Epilepsy: a comprehensive textbook 2008, Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia. 2nd ed.
20. Feng J.F., Gurkoff G.G., Van K.C., Song M., Lowe D.A., Zhou J., et al. NAAG peptidase inhibitor reduces cellular damage in a model of TBI with secondary hypoxia. Brain Res 2012, 1469:144-152.
21. Feng J.F., Van K.C., Gurkoff G.G., Kopriva C., Olszewski R.T., Song M., et al. Post-injury administration of NAAG peptidase inhibitor prodrug, PGI-02776, in experimental TBI. Brain Res 2011, 1395:62-73.
22. Forloni G., Grzanna R., Blakely R.D., Coyle J.T. Co-localization of N-acetyl-aspartyl-glutamate in central cholinergic, noradrenergic, and serotonergic neurons. Synapse 1987, 1:455-460.
23. Fuhrman S., Palkovits M., Cassidy M., Neale J.H. The regional distribution of N-acetylaspartylglutamate (NAAG) and peptidase activity against NAAG in the rat nervous system. J Neurochem 1994, 62:275-281.
24. Fulham M.J., Dietz M.J., Duyn J.H., Shih H.H., Alger J.R., Di Chiro G. Transsynaptic reduction in N-acetyl-aspartate in cerebellar diaschisis: a proton MR spectroscopic imaging study. J Comput Assist Tomogr 1994, 18:697-704.
25. Grissom R.J., Kim J.J. Effect sizes for research: univariate and multivariate applications 2012, Routledge, New York. 2nd ed.
26. Gurkoff G.G., Feng J.F., Van K.C., Izadi A., Ghiasvand R., Shahlaie K., et al. NAAG peptidase inhibitor improves motor function and reduces cognitive dysfunction in a model of TBI with secondary hypoxia. Brain Res 2013, 1515:98-107.
27. Hetherington H.P., Kim J.H., Pan J.W., Spencer D.D. 1H and 31P spectroscopic imaging of epilepsy: spectroscopic and histologic correlations. Epilepsia 2004, 45(Suppl. 4):17-23.
28. Hlouchová K., Bařinka C., Klusák V., Šácha P., Mlčochová P., Majer P., et al. Biochemical characterization of human glutamate carboxypeptidase III. J Neurochem 2007, 101:682-696.
29. Koller K.J., Zaczek R., Coyle J.T. N-acetyl-aspartyl-glutamate: regional levels in rat brain and the effects of brain lesions as determined by a new HPLC method. J Neurochem 1984, 43:1136-1142.
30. Lallement G., Carpentier P., Collet A., Pernot-Marino I., Baubichon D., Sentenac-Roumanou H., et al. Implication du système glutamatergique de l'amygdale au cours des crises généralisées provoquées par le soman: comparaison avec l'hippocampe. C R Acad Sci III 1991, 313:421-426.
31. Lallement G., Carpentier P., Pernot-Marino I., Baubichon D., Collet A., Blanchet G. Involvement of the different rat hippocampal glutamatergic receptors in development of seizures induced by soman: an autoradiographic study. Neurotoxicology 1991, 12:655-664.
32. Lallement G., Denoyer M., Collet A., Pernot-Marino I., Baubichon D., Monmaur P., et al. Changes in hippocampal acetylcholine and glutamate extracellular levels during soman-induced seizures: influence of septal cholinoceptive cells. Neurosci Lett 1992, 139:104-107.
33. Lodder-Gadaczek J., Becker I., Gieselmann V., Wang-Eckhardt L., Eckhardt M. N-acetylaspartylglutamate synthetase II synthesizes N-acetylaspartylglutamylglutamate. J Biol Chem 2011, 286:16693-16706.
34. Lu X.M., Tang Z., Liu W., Lin Q., Slusher B.S. N-acetylaspartylglutamate protects against transient focal cerebral ischemia in rats. Eur J Pharmacol 2000, 408:233-239.
35. Madhavarao C.N., Namboodiri A.M. NAA synthesis and functional roles. Adv Exp Med Biol 2006, 576:49-66.
36. McDonough J.H., Shih T.M. Neuropharmacological mechanisms of nerve agent-induced seizure and neuropathology. Neurosci Biobehav Rev 1997, 21:559-579.
37. Moffett J.R., Arun P., Ariyannur P.S., Garbern J.Y., Jacobowitz D.M., Namboodiri A.M. Extensive aspartoacylase expression in the rat central nervous system. Glia 2011, 59:1414-1434.
38. Motulsky H. Intuitive biostatistics 2010, Oxford University Press, New York. 2nd ed.
39. Myhrer T. Identification of neuronal target areas for nerve agents and specification of receptors for pharmacological treatment. Neurotoxicology 2010, 31:629-638.
40. Myhrer T., Enger S., Jonassen M., Aas P. Enhanced efficacy of anticonvulsants when combined with levetiracetam in soman-exposed rats. Neurotoxicology 2011, 32:923-930.
41. Myhrer T., Nguyen N.H., Andersen J.M., Aas P. Protection against soman-induced seizures in rats: relationship among doses of prophylactics, soman, and adjuncts. Toxicol Appl Pharmacol 2004, 196:327-336.
42. Neale J.H. N-acetylaspartylglutamate (NAAG) is an agonist at mGluR3 in vivo and in vitro. J Neurochem 2011, 119:891-895.
43. Neale J.H., Bzdega T., Wroblewska B. N-acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J Neurochem 2000, 75:443-452.
44. Neale J.H., Olszewski R.T., Gehl L.M., Wroblewska B., Bzdega T. The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. Trends Pharmacol Sci 2005, 26:477-484.
45. Neale J.H., Olszewski R.T., Zuo D., Janczura K.J., Profaci C.P., Lavin K.M., et al. Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family. J Neurochem 2011, 118:490-498.
46. Orlando L.R., Luthi-Carter R., Standaert D.G., Coyle J.T., Penney J.B., Young A.B. N-acetylaspartylglutamate (NAAG) protects against rat striatal quinolinic acid lesions in vivo. Neurosci Lett 1997, 236:91-94.
47. Osborne J.W. Best practices in data cleaning 2013, Sage Publications, Inc., Los Angeles.
48. Passani L.A., Vonsattel J.P., Carter R.E., Coyle J.T. N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated α-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases. Mol Chem Neuropathol 1997, 31:97-118.
49. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2005, Elsevier Academic Press, Boston. 5th ed.
50. Petroff O.A.C., Duncan J.S. Magnetic resonance spectroscopy. Epilepsy: a comprehensive textbook 2008, 975-988. Lippincott, Williams & Wilkins, Philadelphia. 2nd ed. J. Engel, T.A. Pedley (Eds.).
51. Puttfarcken P.S., Handen J.S., Montgomery D.T., Coyle J.T., Werling L.L. N-acetyl-aspartylglutamate modulation of N-methyl-d-aspartate-stimulated [3H]norepinephrine release from rat hippocampal slices. J Pharmacol Exp Ther 1993, 266:796-803.
52. Robinson M.B., Blakely R.D., Couto R., Coyle J.T. Hydrolysis of the brain dipeptide N-acetyl-l-aspartyl-l-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J Biol Chem 1987, 262:14498-14506.
53. Sanchez-Prieto J., Budd D.C., Herrero I., Vazquez E., Nicholls D.G. Presynaptic receptors and the control of glutamate exocytosis. Trends Neurosci 1996, 19:235-239.
54. Schmued L.C., Stowers C.C., Scallet A.C., Xu L. Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons. Brain Res 2005, 1035:24-31.
55. Schuff N., Meyerhoff D.J., Mueller S., Chao L., Sacrey D.T., Laxer K., et al. N-acetylaspartate as a marker of neuronal injury in neurodegenerative disease. Adv Exp Med Biol 2006, 576:241-262.
56. Sekiguchi M., Okamoto K., Sakai Y. Low-concentration N-acetylaspartylglutamate suppresses the climbing fiber response of Purkinje cells in guinea pig cerebellar slices and the responses to excitatory amino acids of Xenopus laevis oocytes injected with cerebellar mRNA. Brain Res 1989, 482:87-96.
57. Serles W., Li L.M., Antel S.B., Cendes F., Gotman J., Olivier A., et al. Time course of postoperative recovery of N-acetyl-aspartate in temporal lobe epilepsy. Epilepsia 2001, 42:190-197.
58. Shih T.M., McDonough J.H. Organophosphorus nerve agents-induced seizures and efficacy of atropine sulfate as anticonvulsant treatment. Pharmacol Biochem Behav 1999, 64:147-153.
59. Slusher B.S., Vornov J.J., Thomas A.G., Hurn P.D., Harukuni I., Bhardwaj A., et al. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med 1999, 5:1396-1402.
60. Thomas A.G., Liu W., Olkowski J.L., Tang Z., Lin Q., Lu X.C., et al. Neuroprotection mediated by glutamate carboxypeptidase II (NAALADase) inhibition requires TGF-β. Eur J Pharmacol 2001, 430:33-40.
61. Thomas A.G., Wozniak K.M., Tsukamoto T., Calvin D., Wu Y., Rojas C., et al. Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy. Adv Exp Med Biol 2006, 576:327-337.
62. Tortella F.C., Lin Y., Ved H., Slusher B.S., Dave J.R. Neuroprotection produced by the NAALADase inhibitor 2-PMPA in rat cerebellar neurons. Eur J Pharmacol 2000, 402:31-37.
63. Tsai G., Stauch B.L., Vornov J.J., Deshpande J.K., Coyle J.T. Selective release of N-acetylaspartylglutamate from rat optic nerve terminals in vivo. Brain Res 1990, 518:313-316.
64. Van Hemelrijck A., Hachimi-Idrissi S., Sarre S., Ebinger G., Michotte Y. Neuroprotective effect of N-acetyl-aspartyl-glutamate in combination with mild hypothermia in the endothelin-1 rat model of focal cerebral ischaemia. J Neurochem 2005, 95:1287-1297.
65. Weissman B.A., Raveh L. Therapy against organophosphate poisoning: the importance of anticholinergic drugs with antiglutamatergic properties. Toxicol Appl Pharmacol 2008, 232:351-358.
66. Williamson L.C., Eagles D.A., Brady M.J., Moffett J.R., Namboodiri M.A., Neale J.H. Localization and synaptic release of N-acetylaspartylglutamate in the chick retina and optic tectum. Eur J Neurosci 1991, 3:441-451.
67. Wroblewska B. NAAG as a neurotransmitter. Adv Exp Med Biol 2006, 576:317-325.
68. Yanagisawa N., Morita H., Nakajima T. Sarin experiences in Japan: acute toxicity and long-term effects. J Neurol Sci 2006, 249:76-85.
69. Yourick D.L., Koenig M.L., Durden A.V., Long J.B. N-acetylaspartylglutamate and β-NAAG protect against injury induced by NMDA and hypoxia in primary spinal cord cultures. Brain Res 2003, 991:56-64.
70. Zhong C., Luo Q., Jiang J. Blockade of N-acetylaspartylglutamate peptidases: a novel protective strategy for brain injuries and neurological disorders. Int J Neurosci 2014, 124:867-873.
71. Zhong C., Zhao X., Sarva J., Kozikowski A., Neale J.H., Lyeth B.G. NAAG peptidase inhibitor reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion TBI in rats. J Neurotrauma 2005, 22:266-276.
72. Zhong C., Zhao X., Van K.C., Bzdega T., Smyth A., Zhou J., et al. NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat. J Neurochem 2006, 97:1015-1025.
73. Zhou J., Neale J.H., Pomper M.G., Kozikowski A.P. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov 2005, 4:1015-1026.
74. Zimmer L.A., Ennis M., Wiley R.G., Shipley M.T. Nerve gas-induced seizures: role of acetylcholine in the rapid induction of Fos and glial fibrillary acidic protein in piriform cortex. J Neurosci 1998, 18:3897-3908.